Selecting this disease as the case in this study is primarily because TNBC treatment (e.g., classical regimens) still remains challenging compared to other types of breast cancer, given the lack of specific hormone receptors, common driver mutations (Rajput et al., 2016; Zhu et al., 2022), and high heterogeneity and resistance (Nedeljković and Damjanović, 2019). Here, NR4A1 is linked to breast carcinoma.